[Molecular diagnosis of and molecular targeting therapy for leukemia]

Yoko Tabe1

  • 1Department of Clinical Pathology, Juntendo University of Medicine, Bunkyo-ku, Tokyo 113-8421, Japan. tabe@juntendo.ac.jp

Rinsho Byori. the Japanese Journal of Clinical Pathology
|March 26, 2009
PubMed

Insights

Targeting leukemia cell signaling pathways and the bone marrow microenvironment can overcome drug resistance. Novel therapies involving histone acetylation and flow cytometry show promise for leukemia treatment and diagnosis.

Area of Science:

  • Molecular biology
  • Cancer research
  • Hematology

Context:

  • Leukemia cell survival is influenced by signaling pathways and the bone marrow microenvironment.
  • Leukemic cells can develop chemo-resistance within specific bone marrow niches.
  • Understanding leukemia-stroma interactions is crucial for developing effective therapies.

Purpose:

  • To investigate novel therapeutic interventions targeting microenvironment/leukemia crosstalk.
  • To explore the role of chromatin modification and nuclear receptors in gene regulation in leukemia.
  • To evaluate the utility of phospho-specific flow cytometry in leukemia diagnosis and research.

Summary:

  • Therapeutic strategies targeting SDF1/CXCR4, ILK/PI3K/Akt, TGF-beta, and Notch signaling pathways are proposed.
  • Histone acetylation using PPARgamma agonist CDDO and RAR/RXR agonist ATRA, along with histone deacetylase inhibitors (HDACIs), can reverse gene silencing and induce apoptosis in leukemia cells.
  • Phospho-specific flow cytometry is utilized to analyze protein phosphorylation in acute myeloid leukemia (AML) and detect ZAP-70 in chronic lymphocytic leukemia (CLL).

Impact:

  • Findings may lead to the development of strategies to overcome chemo-resistance in leukemia.
  • Research contributes to understanding gene regulation in leukemia through chromatin modification.
  • Flow cytometry applications enhance molecular diagnosis and targeted therapy for leukemia patients.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...